Valuation: Nexstim Plc

Market Cap 79.38M 90.8M 72.95M 67.99M 129M 8.65B 131M 876M 340M 4.25B 341M 334M 14.64B P/E 2026 *
81.9x
P/E 2027 * 36.4x
Enterprise Value 77.28M 88.4M 71.02M 66.2M 126M 8.42B 127M 853M 331M 4.14B 332M 325M 14.26B EV / Sales 2026 *
6.08x
EV / Sales 2027 * 4.7x
Free-Float
58.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 49 2020-02-10
Director of Finance/CFO 40 2020-02-10
Chief Tech/Sci/R&D Officer 65 2007-12-31
Director TitleAgeSince
Director/Board Member 64 2019-11-10
Chairman 63 2019-11-10
Director/Board Member 55 2021-04-30
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 90.8M
+1.97%+2.03%+21.92%+0.55% 195B
+5.87%+5.27%-21.76%+27.59% 151B
+2.17%+0.89%-2.59%-16.62% 140B
+4.83%+2.06%-56.73%-15.23% 67.09B
+2.59%+3.95%+22.89%+3.75% 54.34B
+0.03%+2.19%-25.17%-30.62% 44.63B
+0.31%+1.30%+8.30%+42.29% 37.24B
-2.02%-3.91%+7.67%+9.36% 36.91B
+4.24%+4.66%-18.42%-3.15% 30.24B
Average +2.00%+2.74%-7.10%+1.99% 83.99B
Weighted average by Cap. +2.78%+3.44%-4.01%+2.09%

Financials

2026 *2027 *
Net sales 12.7M 14.53M 11.67M 10.88M 20.63M 1.38B 20.95M 140M 54.47M 680M 54.53M 53.36M 2.34B 16.1M 18.42M 14.8M 13.79M 26.16M 1.75B 26.56M 178M 69.05M 862M 69.13M 67.65M 2.97B
Net income 1M 1.14M 919K 857K 1.62M 109M 1.65M 11.03M 4.29M 53.54M 4.29M 4.2M 184M 2.2M 2.52M 2.02M 1.88M 3.57M 240M 3.63M 24.27M 9.44M 118M 9.45M 9.24M 406M
Net Debt -2.1M -2.4M -1.93M -1.8M -3.41M -229M -3.46M -23.17M -9.01M -112M -9.02M -8.82M -387M -3.7M -4.23M -3.4M -3.17M -6.01M -403M -6.1M -40.82M -15.87M -198M -15.89M -15.55M -683M
Logo Nexstim Plc
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
40
Trader
Investor
Global
Quality
ESG MSCI
-